Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE combined with apatinib and camrelizumab for early recurrent hepatocellular carcinoma
ChiCTR2100046533Phase 2Recruiting
- Sponsor
- Department of Hepatobiliary Surgery, Second Affiliated Hospital of Army Medical University
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Department of Hepatobiliary Surgery, Second Affiliated Hospital of Army Medical University. Primary endpoint: progression-free survival. Started May 2021; status: recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100046533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046533.